In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mithra Pharmaceuticals SA

www.mithra.com

Latest From Mithra Pharmaceuticals SA

Deal Watch: Another Delay For Roche/Spark, While FTC Ups AbbVie/Allergan Merger Scrutiny

Tender deadline for Roche acquisition of Spark pushed back to 30 October; 21.4% of Spark shares tendered so far. Vertex further diversifies with fourth deal of 2019 – an RNA-targeted collaboration with Ribometrix.

Deals M & A

Dr Reddy's Is Knocked Back On US NuvaRing And Copaxone Rivals

Dr Reddy’s has received a further CRL from the US Food and Drug Administration over its application for a generic rival to Merck Sharp & Dohme’s NuvaRing contraceptive, along with a CRL for its version of Teva’s Copaxone.

Regulation United States

Pipeline Watch: Phase III Progress With BL-8040, Recorlev And Estelle

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals

Pipeline Watch: Top-line Phase III Results For KX2-391, Dasotraline And Brigatinib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Implantable Devices
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
    • Generic Drugs
    • Nutraceuticals
    • OTC, Consumer
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Gynecological, Urological
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Belgium
  • Parent & Subsidiaries
  • Mithra Pharmaceuticals SA
  • Senior Management
  • Francois Fornieri, CEO & Chief Bus. Dev. Officer
    Graham Dixon, PhD, CSO
    Michaël Dillen, VP, Corp. Dev.
    Jean-Manuel Fontaine, VP, External & Scientific Affairs
    Patrick Kellens, CIO
  • Contact Info
  • Mithra Pharmaceuticals SA
    Phone: 4 349 28 22
    Rue Saint-Georges 5
    Liège, 4000
    Belgium
UsernamePublicRestriction

Register